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OBJECTIVE—Adiponectin is an adipocyte-derived hormone
that plays an important role in glucose and lipid metabolism. The
main aims of this study are to investigate the effects of adiponec-
tin on VLDL triglyceride (VLDL-TG) metabolism and the under-
lying mechanism.
RESEARCH DESIGN AND METHODS—Adenoviruses were
used to generate a mouse model with elevated circulating
adiponectin. HepG2 and C2C12 cells were treated with recombi-
nant human adiponectin.
RESULTS—Three days after Ad-mACRP30 adenovirus injection,
plasma adiponectin protein levels were increased 12-fold. All
three main multimeric adiponectin molecules were proportion-
ally elevated. Fasting plasma TG levels were signiﬁcantly
decreased (40%) in the mice with elevated adiponectin in
circulation, as were the plasma levels of large and medium
VLDL subclasses. Although apolipoprotein B mRNA levels
were robustly suppressed in the livers of adiponectin-overex-
pressing mice and in cultured HepG2 cells treated with
recombinant human adiponectin, hepatic VLDL-TG secretion
rates were not altered by elevated plasma adiponectin. How-
ever, Ad-mACRP30–treated mice exhibited a signiﬁcant in-
crease of postheparin plasma lipoprotein lipase (LPL) activity
compared with mice that received control viral vector. Skele-
tal muscle LPL activity and mRNA levels of LPL and VLDL
receptor (VLDLr) were also increased in Ad-mACRP30–
treated mice. Recombinant human adiponectin treatment in-
creased LPL and VLDLr mRNA levels in differentiated C1C12
myotubes.
CONCLUSIONS—These results suggest that adiponectin de-
creases plasma TG levels by increasing skeletal muscle LPL and
VLDLr expression and consequently VLDL-TG catabolism.
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D
yslipidemia is a major component of the meta-
bolic syndrome and a strong risk factor for the
development of cardiovascular disease. Adi-
ponectin is an adipocyte-derived hormone that
enhances insulin sensitivity and plays an important role in
glucose metabolism (1). Paradoxically, adiponectin gene
expression is diminished with the development of obesity
(1). Thus, hypoadiponectinemia and dyslipidemia are com-
monly observed in obesity and obesity-associated meta-
bolic syndrome. In addition, studies have shown that
plasma adiponectin levels are inversely correlated with
VLDL triglyceride (VLDL-TG) and positively correlated
with HDL cholesterol (2–4), which suggest that adiponec-
tin may inﬂuence in lipid metabolism.
Effects of adiponectin on lipid metabolism have been
studied in adiponectin transgenic and gene-deﬁcient
mouse models. In adiponectin transgenic mice, although
plasma adiponectin is only moderately elevated, plas-
ma TG concentrations are markedly reduced (5–7). In
contrast, hypertriglyceridemia has been reported in
adiponectin-deﬁcient mice (8). Furthermore, administra-
tion of adiponectin normalized high-fat diet–induced hy-
pertriglyceridemia in mice (9). These studies demonstrate
that adiponectin plays an important role in TG metabo-
lism. However, the mechanism by which adiponectin
regulates TG metabolism is largely unknown.
VLDL is the main carrier of circulating TG during
fasting. Plasma VLDL-TG level is determined by the bal-
ance of VLDL-TG hepatic secretion and catabolism in
peripheral tissues. VLDL-TG is synthesized and secreted
by hepatocytes after a series of complex intracellular
events involving the synthesis of apolipoprotein B (apoB)
and lipid and their assembly into lipoprotein particles. TG
is the main lipid component of VLDL. At the luminal
surface of capillaries in peripheral tissues, VLDL-TG is
hydrolyzed by lipoprotein lipase (LPL) with the release of
fatty acids, which are transported into adipocytes for
storage or into heart and skeletal muscle for oxidation as
fuel (10).
To determine the effect and underlying mechanism of
adiponectin on TG metabolism, a mouse model with acute
elevation of plasma adiponectin was generated for this
study using adenovirus-mediated gene transduction. Re-
combinant human adiponectin and cultured myotubes
were also used. Our study showed that elevation of plasma
adiponectin reduced fasting circulating TG in mice. De-
spite decreased apoB mRNA levels in adiponectin-overex-
pressing mice, elevated adiponectin did not affect hepatic
VLDL-TG or hepatic apoB protein secretion. Increases in
plasma adiponectin did not alter mean VLDL particle size.
However, the large and medium VLDL subclass particle
concentrations were signiﬁcantly reduced in adiponectin-
overexpressed mice. Furthermore, signiﬁcant increases of
postheparin LPL activity and of LPL and VLDL receptor
(VLDLr) expression in skeletal muscle were observed in
the mice with elevated adiponectin. Therefore, we propose
that adiponectin reduces plasma TG by increasing LPL,
VLDLr expression, and VLDL-TG catabolism in peripheral
tissues.
RESEARCH DESIGN AND METHODS
Recombinant human adiponectin and anti-mouse adiponectin antibody were
purchased from R&D Systems (Minneapolis, MN). Poloxamer-407 was gener-
ously provided by BASF (Mount Olive, NJ). Fatty acid–free BSA and actino-
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1824 DIABETES, VOL. 57, JULY 2008mycin D were purchased from Sigma (St. Louis, MO). The L-type TG-H and
HDL cholesterol kits were purchased from Wako Diagnostics (Richmond, VA).
Penicillin, streptomycin, Dulbecco’s modiﬁed Eagle’s medium (DMEM), and
horse serum were purchased from Invitrogen (Carlsbad, CA).
Male C57BL/6J mice were purchased from The Jackson Laboratories (Bar
Harbor, ME). All mice were maintained under standardized conditions with
12-h/12-h light/dark cycle and used between 8 and 10 weeks. The mice were
randomly divided into two groups (n  6). The experiments using mouse
models were carried out under the Association for Assessment and Accredi-
tation of Laboratory Animal Care guidelines with approval of the University of
Kentucky Animal Care and Use Committee. Puriﬁed adenoviruses were
diluted in PBS immediately before infusion. The adenovirus was injected
through tail vein with a dosage of 1  10
9 plaque-forming units/mouse in
100-l volume (11). Most experiments were conducted 3 days after injection
unless otherwise stated. Adenovirus-encoding green ﬂuorescent protein
(GFP) was used as control.
Cell culture. HepG2 and C2C12 myoblasts were purchased from American
Type Culture Collection. The cells were maintained in DMEM supplemented
with 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA), 200
mmol/l L-glutamine, 200 units/ml penicillin, and 50 g/ml streptomycin in an
atmosphere of 95% air and 5% CO2. When C2C12 cells reached 90% conﬂuency,
myotube differentiation was induced by switching the medium to DMEM
supplemented with 2% horse serum. The culture medium was changed daily.
Multinucleated myotubes were obtained within 4 days. For adiponectin
treatment studies, both HepG2 and C2C12 myotubes were washed twice with
PBS. Recombinant human adiponectin (10 g/ml) was added to serum-free
DMEM and cultured overnight or for the indicated times.
mRNA stability measurement. After treating HepG2 cells with adiponectin
overnight, 10 g/ml actinomycin D was added into medium. The cells were
further cultured for the indicated times. Total mRNA was extracted and
mRNA levels were quantiﬁed by real-time PCR using primers listed in Table 1.
18S ribosomal RNA was used as an internal control.
Hepatic VLDL-TG secretion and apoB secretion. Hepatic VLDL-TG secre-
tion and apoB secretion rates were measured using poloxamer-407, which
inhibits endogenous LPL with fewer adverse effects on lipoprotein metabolism
than Triton WR-1339 (12). Mice were fasted for 4 h before detergent injection.
Poloxamer-407 was dissolved in PBS and injected into mouse (1,000 mg/kg)
through tail vein (12). Blood samples were drawn in heparin capillary tubes at
the indicated times, and serum TG concentrations were measured using a
Wako kit. ApoB protein levels were quantiﬁed by Western blotting. Serum
samples were prepared in nonreducing protein loading buffer (10 mmol/l
Tris-HCl, 5% glycerol, and 1% SDS, pH 6.8) or twofold concentrated Laemmli
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, and 0.125 mol/l Tris-HCl,
pH 6.8) without boiling. The anti-mouse apoB-48/100 antibody was purchased
from Meridian Life Science (Saco, ME). The antibody was speciﬁcally de-
signed to recognize both apoB-100 and apoB-48.
The total lipoprotein fraction of plasma (100 l) was prepared by gel
ﬁltration chromatography using a Superose 6 10/300GL column (GE), run at a
ﬂow rate of 0.5 ml/min. Fractions were collected at 0.5-min intervals. Total
cholesterol concentrations of fractions were measured and plotted to identify
the positions of the major lipoprotein classes. Fractions of 25 l (12–35) were
mixed with nonreducing protein loading buffer and separated by SDS-PAGE.
ApoB protein was probed by Western blotting.
LPL activity measurement. Postheparin and tissue LPL activity was mea-
sured using a kit and protocol provided by the manufacturer (Research
Diagnostics). Fluorescent TG, which is intramolecularly quenched by a
trinitrophenyl group, was used as substrate. Hydrolysis by lipase results in
pyrene ﬂuorescence. Hepatic lipase activity can be distinguished in the
presence of 1 mol/l NaCl, which totally abolishes LPL activity. Plasma samples
were collected from mice 5 min after a tail vein injection of 300 units/kg
heparin (13). Tissue samples were collected after overnight fasting and
homogenized for LPL activity measurement.
Lipoprotein particle size and subclass proﬁle. Three days after virus
injection and overnight fasting, blood samples were collected by heart
puncture. Plasma was prepared and stored at 4°C. Assays were carried out
within 3 days after collecting plasma samples. Lipoprotein particle size and
subclass proﬁle were analyzed using whole-plasma sample and nuclear
magnetic resonance (NMR) lipoProﬁle-II at LipoScience (Raleigh, NC). All
lipoprotein particle concentrations are provided in units of moles of particle
per liter (14). One mole of particles equals 6.02  10
23 particles per liter. The
measured NMR signal amplitude from each lipoprotein subclass is directly
proportional to the particle concentration of that subclass and not the amount
of cholesterol or TG in that particle (14).
Plasmid constructs and generation of adenovirus. Mouse adiponectin
cDNA was cloned by RT-PCR and inserted into pENTR vector (Invitrogen).
The sequences of the primers are the following: forward primer, 5-caccag-
gATGgTACTGTTGCAAGC-3; and reverse primer, 5-TCAGTTGGTATCATGG
TAGA-3. Adiponectin-encoding DNA was then transferred to pAd/CMV/V5-
Dest vector using the Gateway technique following protocol provided by the
manufacturer (Invitrogen). Adenovirus was produced in HEK293 cells and
puriﬁed by cesium chloride as described previously (15).
Serum adiponectin immunoblotting. Serum adiponectin protein levels and
adiponectin multimers were analyzed by Western blotting. Blood samples
were collected through the tail vein after overnight fasting. For total adiponec-
tin measurements, serum (0.4 l) was separated by SDS-PAGE using Laemmli
sample buffer. For multimeric adiponectin measurements, serum samples
were prepared by nonreducing loading buffer (1% SDS, 5% glycerol, and 10
mmol/l Tris-HCl, pH 6.8) at room temperature for 10 min and separated by
4–20% gradient SDS-PAGE. Proteins were transferred to polyvinylidine ﬂuo-
ride membrane, and adiponectin was probed with antibody raised against
mouse adiponectin. Protein bands were quantiﬁed using Bio-Rad Chemidoc
system with Quantity 1 software.
Quantitative RT-PCR analysis. Total RNA was prepared from liver tissues,
HepG2 cells, and C2C12 myotubes with TRIzol following the manufacturer’s
protocol (Invitrogen). cDNA was synthesized using SuperScript III Reverse
Transcriptase and oligo(dT)12–18 primer (Invitrogen). Real-time PCR was
performed using a Mx3000P Real-Time PCR system (Stratagene) and SYBR
Green dye (Molecular Probes, Eugene, OR). The sequences for the primers are
listed in Table 1. The levels of PCR product were calculated from standard
curves established for each primer pair. Expression data were normalized to
the amount of 18S rRNA.
Statistical analysis. Data are expressed as mean  SE. Statistical analysis
was performed using the Student’s t test or ANOVA, followed by contrast test
with Tukey’s or Dunnett’s error protection. Differences were considered
signiﬁcant at P  0.05.
RESULTS
Adenovirus-mediated hepatic adiponectin transduc-
tion increases circulating adiponectin in mice. Most
previous animal studies regarding the modulatory effects
of adiponectin on lipid metabolism were conducted in
adiponectin transgenic or gene-deﬁcient mouse models,
which illustrate a long-term impact of adiponectin on lipid
metabolism. A life-time increase or absence of adiponectin
TABLE 1
Primer sequences for real-time PCR
Gene
Sequences (5 to 3)
GenBank Forward Reverse
m-18S rRNA CGAAAGCATTTGCCAAGAAT AGTCGGCATCGTTTATGGTC X00686
m-LPL CAGAGTTTGACCGCCTTCC AATTTGCTTTCGATGTCTGAGAA NM_008509
m-VLDLr GAGCCCCTGAAGGAATGCC CCTATAACTAGGTCTTTGCAGATATGG NM_013703
m-apoB GGCACTGTGGGTCTGGAT TTCTTCTCTGGAGGGGACTG NM_009693
h-apoB TGCTCTCATCAAAGGCATGA TGCTTCCTCTTAGCGTCCAG NM_000384
m-apoC-III CGCTAAGTAGCGTGCAGGA TCTGAAGTGATTGTCCATCCAG NM_023114
h-apoC-III GTGCAGGAGTCCCAGGTG AGTAGTCTTTCAGGGAACTGAAGC NM_000040
m-apoA-V CAGTGTTCGCAAGCACTCAG GAAGCTGCCTTTCAGGTTCTC NM_080434
h-apoA-V AGGCACGGAAAGGCTTCT GCTCAAGGCTGTCTTTCAGG NM_052968
m-CD36 TGGCCTTACTTGGGATTGG CCAGTGTATATGTAGGCTCATCCA NM_007643
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the direct modulatory effects of adiponectin on lipid
metabolism in vivo. To investigate the effects of adiponec-
tin on lipid metabolism, we generated a mouse model with
an acute elevation of plasma adiponectin using adenovi-
rus-mediated in vivo gene transduction (15). Similar
mouse or rat models have been reported in several studies
for other purposes (16,17).
Consistent with our previous study (15), viral vector–
mediated adiponectin gene expression was observed al-
most exclusively in liver tissues (data not shown). Plasma
adiponectin protein levels were measured by Western blot.
As shown in Fig. 1A, a signiﬁcant increase of serum
adiponectin was detected 24 h after viral vector injection.
Serum adiponectin concentration reached maximal levels
around days 4–5. Ad-mACRP30–treated mice exhibited a
12-fold increase of circulating adiponectin 72 h after
injection (Fig. 1B), without any signiﬁcant changes of body
weight compared with Ad-GFP–treated mice (24.45  1.64
vs. 24.10  1.45 g). To minimize any possible effects of
virus-induced inﬂammation, subsequent experiments were
performed 48–72 h after injection. These results demon-
strate that adenovirus vector–mediated adiponectin gene
expression in liver increases adiponectin levels in plasma.
Circulating adiponectin proteins can exist as multimers.
It has been suggested that the different multimeric forms
of adiponectin may have different biological functions or
potency (1,18). Our results showed that adenovirus-medi-
ated adiponectin gene transduction proportionally in-
creased all three main molecular weight adiponectin
multimers in circulation (Fig. 1C).
Adiponectin reduces fasting plasma TG and free fatty
acid in mice. Three days after virus injection, mice were
fasted for 6 h, and plasma total TG and free fatty acid
(FFA) concentrations were determined. As shown in Fig.
2A, plasma TG concentrations were reduced 40% (P 
0.01) in Ad-mACRP30–treated mice. A similar reduction in
plasma FFA was observed (Fig. 2B). Fasting plasma HDL
cholesterol concentrations were signiﬁcantly increased in
Ad-mACRP30–treated mice compared with the control
group (48.08  6.86 vs. 25.59  5.65 mg/dl, P  0.021). The
ﬁnding that adiponectin reduces fasting total TG is consis-
tent with the observed reduction in plasma TG in adi-
ponectin transgenic mice (5). However, 4 h after re-
feeding, the difference of TG between Ad-mACRP30– and
Ad-GFP–treated mice vanished (Supplemental Fig. 1,
available in the online appendix at http://dx.doi.org/
10.2337/db07-0435), presumably due to high levels of
chylomicrons.
An insulin challenge test, conducted 72 h after adenovi-
rus administration, showed that there was no signiﬁcant
difference in insulin-stimulated glucose disposal between
Ad-GFP– and Ad-mACRP30–treated mice (Fig. 2C). In
addition, there was no difference in fasting plasma glucose
concentrations between these two groups of mice (Fig.
2C). Fasting plasma insulin levels in Ad-mACRP30– and
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FIG. 1. Adenovirus-mediated adiponectin overexpression in mice. Puriﬁed adenovirus vectors were
injected into mice through the tail vein. Plasma adiponectin protein levels were measured by Western
blot. A: Time course of total serum adiponectin protein in Ad-mACRP30 viral vector–treated mice. Top
panel is a representative autoradiograph of four mice. B: Serum total adiponectin protein levels were
increased (12-fold) 3 days after viral vector injection. C: Proportional increase of circulating multi-
meric forms of adiponectin in Ad-mACRP30 vector–treated mice. The multimeric forms of adiponectin
were analyzed by nonreducing PAGE. HMW, high molecular weight; MMW, medium molecular weight;
LMW, low molecular weight.
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0.3105  0.01 ng/ml). However, consistent with a previous
study (19), signiﬁcant decreases of PEPCK and glucose-6-
phosphatase mRNA were observed in the livers of mice
with elevated plasma adiponectin (data not shown). More
precise measurements, e.g., hyperinsulinemic-euglycemic
clamps, are required to determine the effect of acutely
increased adiponectin on insulin sensitivity. Our results
imply that adiponectin may modulate lipid metabolism
through a mechanism independent of adiponectin-
enhanced insulin sensitivity.
Adiponectin reduces apoB mRNA but does not alter
hepatic apoB protein secretion. We measured mRNA
levels of apoB and several other apolipoproteins in the
livers of Ad-mACRP30–treated mice to test whether adi-
ponectin regulates apolipoprotein expression. As shown in
Fig. 3A, hepatic apoB mRNA was reduced by nearly 50% in
Ad-mACRP30–treated mice compared with control mice.
The expression of apoE, apoA-I, apoA-V, and apoC-III was
also measured. Studies have reported that adiponectin can
regulate peroxisome proliferator–activated receptor 
(PPAR) (18) and that PPAR regulates both apoA-V and
apoC-III transcription (20,21). However, our results
showed no differences in the mRNA levels of either apoA-V
or apoC-III between Ad-mACRP30– and Ad-GFP–treated
mice (Fig. 3A). However, apoA-I mRNA levels were de-
creased in Ad-mACRP30–treated mice (Fig. 3A).
To further verify these observations, an in vitro study
was carried out using HepG2 hepatocytes and recombi-
nant human adiponectin protein. Consistent with the in
vivo results, the apoB mRNA level was also markedly
suppressed in HepG2 cells after 24 h of 10 g/ml adiponec-
tin treatment (P  0.01; Fig. 3B). Adiponectin treatment
did not alter apoA-V mRNA; however, it reduced apoC-III
mRNA (Fig. 3B). The increase in apoA-I mRNA level after
adiponectin treatment was the opposite of the results of
the in vivo study (Fig. 3A). These differences in the effects
of adiponectin on apoA-I and apoC-III expression in the in
vivo and in vitro studies may reﬂect differences in these
two models.
We also measured the effects of adiponectin treatment
on apoB mRNA stability in HepG2 cells. The results
showed that there was no signiﬁcant difference of apoB
mRNA half-life between adiponectin-treated and control
cells (data not shown). Together, these studies indicate
that adiponectin suppresses hepatic apoB gene expression
without altering apoB mRNA stability, implying that adi-
ponectin inhibits apoB expression at the transcription
level.
While this manuscript was in preparation, Neumeier et
al. (22) reported that adiponectin reduced apoB expres-
sion in human hepatocytes by reducing hepatocyte nuclear
factor-4 (HNF4). However, our study did not show any
changes in HNF4 at both protein (Fig. 4) and mRNA
levels (data not shown). Microsomal TG transfer protein
plays a key role in VLDL assembly in liver. Our studies
showed that the microsomal triglyceride transfer protein
mRNA levels were not signiﬁcantly altered in the livers of
Ad-mACRP30–treated mice or adiponectin-incubated
HepG2 cells (data not shown).
To further study the effect of adiponectin on apoB
expression in liver, basal serum apoB protein levels and
hepatic apoB protein secretion rates were studied using
fasting serum and serum samples collected at different
time points after LPL inhibition by Poloxamer-407 (see
details in RESEARCH DESIGN AND METHODS for measurement of
hepatic VLDL secretion rate). Mouse hepatocytes edit
apoB mRNA, and both apoB-100 and apoB-48 protein can
be produced from mouse liver (23). As shown in Fig. 3C,
despite slightly reduced fasting apoB-100 and apoB-48
levels in Ad-mACRP30–treated mice, there was no statis-
tical difference of basal total apoB protein levels between
Ad-mACRP30– and Ad-GFP–treated mice (P 	 0.05).
Unexpectedly, the fasting plasma apoB-100 band was
markedly shifted in Ad-mACRP30–treated mice under
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FIG. 2. Reduction of serum TG and FFA in adiponectin-overexpressing
mice. Three days after viral vector injection, the mice were fasted for
6 h. Blood samples were collected, and serum TG (A) and FFA (B)
concentrations were measured using Wako kit, n  6. C: Insulin
challenge tests were carried out after overnight fasting, n  5. *P <
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FIG. 3. Adiponectin reduces apoB mRNA but has no effect on hepatic apoB secretion. A: Total mRNA was extracted from livers of mice 3 days after
virus injection. mRNA levels were measured by real-time PCR using 18S as internal control, n  6. B: Conﬂuent HepG2 cells were treated with
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indicated time points after P-407 injection (D). Plasma was separated in SDS-PAGE with nonreducing loading buffer, and apoB protein was
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appeared under reducing conditions (Fig. 3C). These ob-
servations suggest that elevated adiponectin may induce a
conformational change or modiﬁcation of plasma apoB-
100 in the treated mice. Further studies are being under-
taken to identify the mechanism through which
adiponectin alters plasma apoB-100 protein mobility and
its biological consequences.
Results in Supplemental Fig. 2A show that plasma
apoB-100 protein levels are higher than apoB-48 levels in
mice in the fasting state. Plasma lipoproteins were frac-
tionated by fast-protein liquid chromatography, and cho-
lesterol concentrations in the fractions were determined.
Interestingly, the large bulk of apoB-100 in Ad-mACRP30–
treated mice and also control mice was detected in frac-
tions corresponding to the position of LDL (Supplemental
Fig. 2B). The study also showed that at 4 h after inhibition
of LPL by Poloxamer-407 (12,24), there was an expected
large accumulation of apoB-48 and also of apoB-100,
although to a lesser extent (Fig. 3D; Supplemental Fig. 2A).
However, the increased rate of apoB-100 protein was
signiﬁcantly less than of apoB-48 (Supplemental Fig. 2A),
which may be caused by P-407–induced blockage of
formation of new LDL and continued catabolism of preex-
isting LDL (Supplemental Fig. 2B). Therefore, we used
apoB-48 protein accumulation to calculate hepatic apoB
secretion rate (Fig. 3D). Our study showed no signiﬁcant
difference of hepatic apoB-48 secretion between adiponec-
tin-overexpressing and control mice (Fig. 3E). These re-
sults suggest that adiponectin has no effect on hepatic
apoB protein secretion despite reducing apoB mRNA in
hepatocytes.
Elevated plasma adiponectin has no effect on hepatic
VLDL-TG secretion. The rate of hepatic VLDL-TG secre-
tion was directly measured by the technique in which
Poloxamer-407 is used to inhibit endogenous LPL and
VLDL processing (12,24). Serum TG levels increased mark-
edly after Poloxamer-407 addition and at the same rate in
the Ad-mACRP30–treated and control mice. Calculated
hepatic VLDL-TG secretion rates in the two groups of mice
were similar (Fig. 5B). This study indicates that although
adiponectin suppresses apoB transcription, hepatic
VLDL-TG secretion is not inhibited. This conclusion is
supported by previous studies, which suggest that apoB
gene expression in liver is constitutive and that apoB
synthesis is not usually rate limiting for VLDL assembly
and VLDL-TG secretion (25,26).
Decrease of large and medium VLDL particle levels in
adiponectin-overexpressing mice. Studies have demon-
strated that VLDL particle size plays a signiﬁcant role in
VLDL catabolism and that multimeric adiponectin is re-
lated to lipoprotein subclass proﬁles (27). Our studies
showed that blood TG concentrations were signiﬁcantly
reduced in adiponectin-overexpressing mice without an
alteration in the rate of hepatic apoB and VLDL-TG secre-
tion. This raises the question of whether VLDL particle size
is altered in adiponectin-overexpressing mice. We mea-
sured lipoprotein particle size and the subclass proﬁle
using NMR. As shown in Fig. 5C, mean particle sizes of
LDL or HDL were comparable between Ad-mACRP30–
treated and control mice. VLDL mean particle size was
slightly decreased in adiponectin-overexpressing mice but
without statistical signiﬁcance. However, the levels of
large and medium VLDL subclasses in Ad-mACRP30–
treated mice were signiﬁcantly lower than in control mice
(Fig. 5D). Interestingly, small VLDL levels tended to in-
crease in Ad-mACRP30–treated mice (Fig. 5D). These
results are consistent with the human study, which re-
ported that circulating total and high–molecular weight
adiponectin are negatively correlated with large VLDL
particle levels (27).
Postheparin plasma LPL activity is increased in the
mice with elevated plasma adiponectin. The level of
fasting plasma VLDL-TG is determined by the balance of
hepatic VLDL-TG secretion and peripheral VLDL-TG catab-
olism. Our results showed that elevated adiponectin re-
duces serum TG concentrations and has no effect on
hepatic VLDL-TG secretion. Therefore, adiponectin-
induced low-serum TG is most likely caused by increasing
VLDL-TG catabolism.
Our results showed that postheparin plasma LPL activ-
ities were signiﬁcantly increased in mice that received
Ad-mACRP30 treatment (Fig. 6A). Tissue LPL activity was
also measured using homogenized epididymal fat, gastroc-
nemius muscle, or heart. No difference was detected in
LPL activities in epididymal fat or heart between Ad-
mACRP30– and Ad-GFP virus–treated mice (Fig. 6B).
However, skeletal muscle LPL activities were increased by
41% in Ad-mACRP30–treated mice (P  0.05; Fig. 6B).
Adiponectin increases LPL and VLDLr expression in
skeletal muscle. Altered LPL gene expression and post-
translational modiﬁcation are two mechanisms that regu-
late LPL activity. The mRNA levels of LPL were measured
by real-time PCR. Results showed that LPL mRNA was
signiﬁcantly increased in both skeletal muscle and kidney
of Ad-mACRP30–treated mice (P  0.01; Fig. 7A). No
difference was observed in heart, epididymal fat, or liver
between these two groups of mice.
To further verify the effects of adiponectin on LPL
expression, cultured C2C12 myotubes were treated with
10 g/ml recombinant human adiponectin. A 24-h incuba-
tion of cells with adiponectin signiﬁcantly increased LPL
mRNA levels, consistent with the results from the in vivo
studies (P  0.05; Fig. 7B). These data indicate that
adiponectin directly increases LPL gene expression in
skeletal muscle.
VLDLr plays an important role in VLDL-TG catabolism.
It not only interacts with and enhances LPL activity but
also binds and internalizes VLDL remnants into cells (28).
We measured VLDLr mRNA levels and found that they
were robustly increased (3.6-fold) in skeletal muscle of
Ad-mACRP30–treated mice (P  0.001; Fig. 7C). In con-
trast, the VLDLr mRNA levels in epididymal fat, heart, and
ACRP30
HNF4α
α-tubulin
Ad-GFP     Ad-mACRP30
FIG. 4. Elevated adiponectin has no effect on HNF4 protein levels in
mouse liver. Three days after viral vector injection, liver tissues were
collected in the fasting state after perfusion. Total liver protein was
prepared, and HNF4 and adiponectin were analyzed by Western
blotting.
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control mice (data not shown). A robust increase of VLDLr
mRNA levels was also observed in adiponectin-treated
C2C12 myotubes (P  0.05; Fig. 7D).
Fatty acid translocase (FAT/CD36) is one of the main
proteins that facilitate fatty acid diffusion across plasma
membrane. Our study showed that CD36 mRNA levels
were not altered in either skeletal muscle of
Ad-mACRP30–treated mice or human adiponectin–incu-
bated myotubes (Fig. 7C and D).
DISCUSSION
Although compelling evidence indicates that adiponectin
modulates lipid metabolism, the underlying mechanisms
are largely unknown. Using adenovirus-mediated adi-
ponectin overexpression in vivo and a cultured cellular
model, our current study speciﬁcally investigated the
modulatory effect of adiponectin on VLDL-TG metabolism.
Consistent with previous studies, our study showed that
elevated adiponectin reduces plasma TG in mice. Despite
the decrease of apoB mRNA levels in the livers of Ad-
mACRP30–treated mice and in adiponectin-treated HepG2
hepatocytes, elevated adiponectin did not alter hepatic
VLDL-TG or apoB protein secretion in mice. On the other
hand, skeletal muscle LPL transcription and postheparin
plasma LPL activities, together with VLDLr transcription,
were robustly increased in adiponectin-overexpressing
mice. Consistent with these ﬁndings, recombinant adi-
ponectin increased LPL and VLDLr gene expression in
cultured skeletal muscle cells. Therefore, we propose that
adiponectin reduces plasma TG by increasing VLDL catab-
olism in skeletal muscle.
Since the discovery of the insulin-sensitizing property of
adiponectin, numerous studies have observed an inverse
relationship between plasma TG and adiponectin levels.
Studies using adiponectin transgenic or gene-deﬁcient
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metabolism (5–9). However, transgenic or gene-deﬁcient
mouse models represent long-term effects of increased or
absent adiponectin on lipid metabolism. Using adenovirus-
mediated gene transduction technique, we generated a
mouse model with acute elevations of plasma adiponectin.
Our study shows that an acute increase of circulating
adiponectin reduces serum TG and also increases HDL
cholesterol in mice. Together, our study further conﬁrms
that adiponectin improves the anti-atherogenic lipoprotein
proﬁle in mice. A recent study suggested that the positive
link between HDL and adiponectin may be caused by
reduced apoA1 degradation (29). Our study found a de-
crease of apoA1 mRNA in the livers of adiponectin-
overexpressing mice, but an opposite effect was observed
in HepG2 cells (Fig. 3A and B). Further studies are
required to elucidate the underlying mechanism by which
adiponectin increases HDL cholesterol.
ApoB is the major apolipoprotein in VLDL, and both
apoB-100 and apoB-48 are produced in rodent hepatocytes
(23). The results from our in vivo and in vitro studies show
that adiponectin suppresses apoB transcription in hepato-
cyte, which is in agreement with the ﬁndings of a most
recent report (22). Importantly, our in vivo study demon-
strated that adiponectin did not alter basal serum apoB
protein levels or the rate of hepatic apoB secretion despite
decreasing apoB transcription. These results are in line
with previous reports that hepatic apoB mRNA is abun-
dant and that the rate of apoB translation exceeds apoB
secretion (25,26). Thus, the majority of newly synthesized
apoB protein is degraded within hepatocytes before li-
poprotein assembly and secretion (26,30). In addition, our
study found that adiponectin overexpression did not alter
liver VLDL-TG secretion in mice. These results lead us to
conclude that although adiponectin reduces hepatic apoB
gene transcription, adiponectin has no signiﬁcant effect on
hepatic apoB and VLDL-TG secretion. Nevertheless, our
study clearly showed that fasting plasma TG was de-
creased in adiponectin-overexpressing mice. Therefore,
we postulate that increased VLDL-TG catabolism, rather
than decreased synthesis, accounts for the reduced
plasma TG levels in response to adiponectin.
LPL has been considered a gatekeeper for VLDL-TG
catabolism (10). LPL hydrolyzes VLDL-TG and releases
fatty acids for oxidation as fuel for skeletal or cardiac
muscle or for storage in adipose tissue (10,31). Recent
studies have reported a positive relationship between
plasma adiponectin levels and postheparin LPL activities
(32,33). Consistent with these correlative human studies,
our study demonstrated that there was signiﬁcant increase
of postheparin LPL activity in the mice with elevated
adiponectin. These data indicate that adiponectin in-
creases VLDL-TG hydrolysis in peripheral tissues, thus
leading to a decrease in circulating TG. Furthermore, our
study showed that LPL expression and activity were
increased in skeletal muscle from the mice with elevated
adiponectin. In fasted animals, adipose tissue LPL expres-
sion and activity are suppressed, and plasma LPL is mainly
contributed by skeletal muscle and heart (34). Skeletal
muscle plays an important role in TG clearance, taking
into account its large mass in the body. Therefore, in-
creased postheparin LPL activities in adiponectin-overex-
pressing mice were likely due to increased skeletal muscle
LPL expression. A previous study has reported that adi-
ponectin increased TG clearance by increasing LPL ex-
pression in white adipose tissues in female adiponectin
transgenic mice (5). However, our study did not show a
signiﬁcant increase of LPL expression and activity in
epididymal fat of adiponectin-overexpressing mice. Differ-
ences between these animal models may cause the dis-
crepancy. The mouse model we used is acute adiponectin
overexpression. In addition, adiponectin was ectopically
overexpressed and secreted from liver after adenovirus
transduction. Under normal physiological conditions, adi-
ponectin is predominantly synthesized in adipose tissues.
Furthermore, our mice were male, unlike the female mice
used in the previous study (5). However, in our current
study and in the previous report (5), serum FFAs were
found to be reduced in adiponectin-overexpressing mice.
VLDLr is a member of LDL receptor family (35). Similar
to LPL, VLDLr is highly abundant in heart, skeletal muscle,
and adipose tissue, whereas it is barely detectable in liver
(35–37). Recent studies demonstrate that VLDLr is in-
volved in VLDL-TG catabolism by interacting with LPL
(13,35–38). Our ﬁndings show that elevation of plasma
adiponectin induced a robust increase of VLDLr mRNA
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DIABETES, VOL. 57, JULY 2008 1831in skeletal muscle and cultured myotubes. Therefore,
we postulate that the combined effects of adiponectin
on VLDLr and LPL in skeletal muscle contribute to
increased VLDL-TG catabolism. Our recent ﬁndings
have revealed that adiponectin enhances LPL gene
transcription via AMP kinase activation in skeletal
muscle (L.Q., J.S., unpublished data). The detailed
mechanisms are under investigation.
In summary, our study indicates that adiponectin re-
duces blood TG but has no effect on hepatic VLDL-TG
secretion. Increased LPL and VLDLr expression in skeletal
muscle and plasma LPL activity were observed in mice
with elevated plasma adiponectin. Therefore, we propose
that adiponectin reduces plasma TG by increasing
VLDL-TG catabolism in skeletal muscle, at least in part by
increasing LPL and VLDLr expression.
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